Adocia SA · EURONEXT:ADOC
Adocia SA — Investor Presentation (May 2018)
40 slides from Adocia SA's investor presentation, May 2018

Slide 1: Adocia Corporate Presentation
ADOCIA CORPORATE PRESENTATION May 2018

Slide 2: Disclaimer
INTRO Disclaimer This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying t

Slide 3: ADOCIA in summary
ADOCIA ADOCIA in summary Business model delivering cost-effective innovation based on already-approved 1 proteins, enhanced with BioChaperone® Key clinical assets including ultra-rapid insulin BC Lispro, modern premix BC 2 Combo, ready-to-use BC Glucagon and BC Pramlintide Insulin 3 $135M licensing

Slide 4: Management Team
ADOCIA Management Team Gérard Soula Olivier Soula Valérie Rémi Soula Steve Daly PhD, MBA PhD, MBA Danaguezian PhD, MBA President & CEO Deputy General Manager, Chief Financial Officer Director of BD & IP US General Manager Co-founder R&D Director Co-founder Co-founder 4 May 2018

Slide 5: Our mission is dedicated to improving lives
ADOCIA Our mission is dedicated to improving lives Develop treatments for diabetes and other metabolic conditions in a more physiologic and affordable way 5 May 2018

Slide 6: BioChaperone Technology
BIOCHAPERONE TECHNOLOGY 6 May 2018

Slide 7: BioChaperone unlocks the potential of proteins and peptides
ADOCIA BioChaperone® unlocks the potential of proteins and peptides and their combinations in a cost-effective way BioChaperone® Proteins and peptides (insulin, GLP-1 RA, pramlintide, (library of molecules) glucagon; teduglutide…) [BioChaperone® Protein] Complex Improved solubility Improved stabi

Slide 8: Adocia is diversifying its portfolio beyond diabetes
ADOCIA Adocia is diversifying its portfolio beyond diabetes Diabetes clinical pipeline Preclinical pipeline In vitro PC Phase I/II Phase III In vitro PC Phase I/II BC Lispro U100 Diabetes THDB BC Lispro U200 BC Gla GLP-1 THDB BC Combo Other indications (BC Gla Lis) BC GLP-2 Short Bowel Syndrome Hins

Slide 9: There remains a real medical need in diabetes
DIABETES There remains a real medical need in diabetes 26M2 Despite 100 years of medical treatment, long-term 415M1 on insulin consequences of diabetes remain a major issue people with diabetes in 2015 There is a need to address the underlying complexity of diabetes With more granularity In

Slide 10: Diabetes in China
CHINA Diabetes in China Chinese treated partients expected to double (from 30 to 60M) in the next 5-7 years3 >100M1 Better diagnosis, better reimbursements, stronger access in remote areas People with diabetes in China Insulin market (CAGR 12%)2 currently dominated by premix insulins Tonghua

Slide 11: BioChaperone Lead Insulin Clinical Programs
BIOCHAPERONE LEAD INSULIN CLINICAL PROGRAMS BIOCHAPERONE LISPRO & BIOCHAPERONE COMBO 11 May 2018

Slide 12: BioChaperone Lispro: an ultra-rapid insulin
BC LISPRO BioChaperone Lispro: an ultra-rapid insulin showing potential best-in-class performance in pens and pumps $7B Novo Nordisk Fiasp® (faster-acting insulin aspart) is the first approved product Prandial Introduced at price parity with Novolog® in Europe insulin market Approved in the US

Slide 13: Partnering BioChaperone Lispro is Adocia's priority
BC LISPRO Partnering BioChaperone Lispro is Adocia’s priority BC Lispro (U100 & U200) has a complete dossier to support Post-meal glycaemia in T1D Phase 3 Accelerated absorption and better post-prandial control for BC Lispro U100 vs. Humalog® vs. Fiasp®, BC Lispro has shown similar fast-on eff

Slide 14: BC Combo: a safer alternative to premix insulin
BC COMBO A safer and more efficient alternative to premix insulin for the treatment of type 2 diabetes Premix insulin provides basal and prandial coverage with 2 injections/day $5B (vs. up to 4 for basal + prandial insulin) 65%1 Premix insulin In China, premix is the main insulin product in volu

Slide 15: BC Combo superior prandial and basal control vs premix
BC COMBO BC Combo has shown superior prandial and basal control compared to premix insulin Post-meal glycemia in T1D 5 successful Phase 1/2 clinical studies (2 in T1D & 3 in T2D)(1,2) Individualized doses In T1D & T2D BC Combo showed superiority vs. Humalog Mix25 (1,2): ∆AUC0-2h In T2D, BC Com

Slide 16: Multihormonal Treatments for Diabetes
MULTIHORMONAL TREATMENTS FOR DIABETES 16 May 2018

Slide 17: Innovative multi-hormonal approaches for diabetes and obesity
RATIONALE Innovative multi-hormonal approaches aim to improve diabetes and obesity management Insulin In combination BC Glargine GLP-1 (T2D) BC Pramlintide rhIns (T1D & T2D) GLP-1 Amylin In combination In a dual-chamber pump BC Glucagon GLP-1 BC Glucagon with Insulin (T1D) (Obesity) Glucagon As a se

Slide 18: Time-sensitive hormonal pattern maintains normo-glycemia
DIABETES In non-diabetic people, a time-sensitive hormonal pattern maintains normo-glycemia Schematic representation of hormonal pattern1 Insulin Without diabetes With Type 1 diabetes (T1D) Level of secretion Amylin (relative scale) Glucagon GLP-1 GLP-1 Glucagon Insulin Amylin 0 1 2 3 4 5 6 0 1 2 3

Slide 19: Amylin, the Other Missing Hormone in Type 1 Diabetes
BC PRAM INS Amylin, the Other Missing Hormone in Type 1 Diabetes Postprandial blood glucose 6 Amylin is co-secreted with insulin by pancreatic beta cells. h u m a n in s u lin in c re m e n ta l p la s m a g lu c o s e ( m m o l/L ) 5 h u m a n in s u lin + a m y lin a n a lo g 4 Secretion of Am

Slide 20: Benefits of co-administering prandial insulin with pramlintide
BC PRAM INS Leveraging the clinically proven benefits of co-administering prandial insulin with pramlintide -3 kg1 -22%1 Pramlintide (amylin analog) three times a day has demonstrated synergistic benefits when administered on top of insulin2 Blood glucose control (T1D) Better glycemic control vs

Slide 21: Multi-hormonal treatment to improve long-term outcomes in T1D
BC PRAM INS Enabling prandial insulin-based multi-hormonal treatment to improve long-term outcomes in T1D Tighter glycemic control lowers the risk of severe complications1, and insulin alone, while life-saving, is insufficient to optimize control Multiple hormonal combinations could be the next

Slide 22: Ready-to-use aqueous formulation of human glucagon
BC GLUCAGON A ready-to-use aqueous formulation of human glucagon for acute and chronic use BioChaperone Glucagon is an aqueous formulation of human glucagon supporting: Ready-to-use rescue treatment for severe hypoglycemia Current market largely underserved due to poor glucagon kits usability1

Slide 23: Positive first-in-man data support further development
BC GLUCAGON Positive first-in-man data support further development Positive first-in-man results. : 180 Preclinical study in pigs Be safe and well tolerated in people with type 1 diabetes Mean blood glucose Efficiently rescue 100% participants from medically-induced Blood Glucose (mg/dL) 160 h

Slide 24: Expanding the Portfolio
EXPANDING THE PORTFOLIO LEVERAGING BIOCHAPERONE TRACK-RECORD TO ADDRESS NEW THERAPEUTIC TARGETS 24 May 2018

Slide 25: Leveraging BioChaperone beyond diabetes
PORTFOLIO EXPANSION Adocia is leveraging BioChaperone® to unlock the potential of proteins and peptides beyond diabetes Adocia intends to expand the use of BioChaperone to bring cost-effective innovation to other therapeutic areas with high unmet needs by leveraging: Extensive BioChaperone® trac

Slide 26: BioChaperone Glucagon-GLP-1 for nondiabetic obesity
BC GCG GLP-1 BioChaperone Glucagon-GLP-1 for the treatment of nondiabetic obesity Obesity prevalence has tripled from 1975 to 2016 globally2, triggering the development of more aggressive treatment regimens: 36.5%1 Based on BioChaperone Glucagon, Adocia has developed injectable combinations of o

Slide 27: BioChaperone GLP-2 for short-bowel syndrome
BC GLP-2 BioChaperone GLP-2: a ready-to-use solution to improve the life of people with short-bowel syndrome (SBS) Approx. 20,000 people with SBS require parenteral nutrition in EU & US1 Prevalence and awareness are growing Gattex® (teduglutide, Shire) is the only approved treatment for these

Slide 28: Key financial elements
ADOCIA Key financial elements Financial summary Shareholders’ equity (March 2018) Analysts Listed on Euronext Paris (ADOC) Free Float Soula Family 22.1 % Jefferies (Peter Welford) 60.0% Kepler Market (Arsène Guekam) 6.9M shares outstanding Oddo (Sébastien Malafosse – Pierre Corby) Louis

Slide 29: Key assets status
ADOCIA Key assets status Clinical programs Preclinical programs BC LISPRO Phase 3-ready asset, available for licensing in US, EU, Japan BC GLUCAGON GLP-1 Partnered with Tonghua Dongbao in April 2018 for China and other First-in-man study planned in Q4 18 New! emerging markets Positive Pha

Slide 30: Thank you for your kind interest
THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 30 May 2018

Slide 31: Appendix
APPENDIX 31 May2018 ADOCIA f-

Slide 32: Top-tier Medical Advisory Board
ADOCIA Adocia is supported by a top-tier Medical Advisory Board 12 highly renowned international thought-leaders: Dr. Jay Skyler, MD, Chairman, University of Miami (US) Dr. Vanita Aroda, MD, MedStar Health Research Institute (US) Dr. Bruce Bode, MD, Emory University (US) Dr. John Buse, MD,

Slide 33: HinsBet: Affordable prandial insulin
HINSBET Affordable prandial insulin for price-sensitive populations HinsBet is a formulation of human insulin designed to act as rapidly as an insulin analog $1B 77% of people with diabetes live in low- and middle-income countries Human prandial For economic reasons, human insulin is the most

Slide 34: HinsBet displays similar early action to fast-acting analog
HINSBET HinsBet displays similar early action to fast-acting insulin analog in T1D patients Early Glucose Infusion Rate (U100)1 Meal-test study in 36 T1D confirmed PD profile in first hour2 (Oct 2016) During first hour after the meal, HinsBet: 70% earlier onset Significantly reduced glucose

Slide 35: Intensification options over basal insulin for T2D
BC GLAR GLP-1 Efficient and affordable intensification options over basal insulin for T2D $2.2B1 Combinations of basal insulin and GLP-1 are a new class of treatment for T2D 2023 Forecast 50% patients are not controlled on basal insulin alone2 Basal-GLP1 2 products recently approved in EU & US

Slide 36: BC Lispro results vs Humalog U100 in T1DM
BC LISPRO Results summary compared to Humalog U100 in T1DM subjects 294-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Biochaperone Lispro: Shorter TMAX, Higher CMAX BioChaperone Lispro in comparison with and Similar Exposure Greater Earlier Exposure: Faster In Humalo

Slide 37: BC Combo results vs Lispro Mix 75/25 in T1DM
BC COMBO Results summary compared to Conventional Lispro Mix 75/25 in T1DM subjects 295-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Mean Unadjusted BG Profiles ± SEM Over 6hr After s.c. Cumulative Percentage of Subjects With BG Values < 63 mg/dL In this solid mixed

Slide 38: BC Combo results vs Humalog 75/25 in T2DM
BC COMBO Results summary compared to Humalog 75/25 in T2DM subjects 942-P in 12-B Clinical Therapeutics/ New Technology-Insulins, June 11, 2016, 76th ADA Scientific Sessions Smoothed GIR Profiles (0-30h) of 0.8 U/kg BioChaperone Combo, 0.8 Smoothed GIR Profiles (0-2h) of 0.8 U/kg BioChaperone In t

Slide 39: Upcoming major diabetes conferences
EVENTS Upcoming major diabetes conferences Adocia will submit abstracts for publication and intends to attend the following conferences: 78th Scientific Sessions of the American Diabetes Association, June 22 - 26, 2018, Orlando, Florida, USA 54th Annual Meeting of the European Association for

Slide 40: Thank you for your kind interest
THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 40 May 2018
Source: Internet Archive copy of adocia.com
More decks from Adocia SA
Q3 2026 Earnings Presentation19 slides · Nov 2, 2026
Investor Presentation (November 2026)33 slides · November 2026
Investor Presentation (June 2026)43 slides · June 2026
Investor Presentation (March 2026)43 slides · March 2026
Investor Presentation (November 2025)42 slides · November 2025
Shareholder Meeting (June 2025)85 slides · Jun 11, 2025